

2020-2021

American Heart Association

Funding from Pharmaceutical and Biotech Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as revenue from the sale of mission-aligned products and services, such as CPR training, and investment earnings.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies and are approved by a committee of national volunteers and executive staff.

Total corporate funding is comprised of unrestricted gifts, special event and program sponsorships and fees from program-related services. Corporate funding represents approximately 16.6 percent of the AHA's \$1.1 billion total revenue.

Funding that the American Heart Association receives from pharmaceutical and biotech companies and device manufacturers is included within total corporate funding and represents approximately 3.7 percent of the association's total revenue.

The revenue figures below include the total amount of funds earned or committed to the American Heart Association during fiscal year 2020-2021, noting that, in some cases, the funds will be received in future years. The chart provides funds from pharmaceutical and biotech companies and device manufacturers in proportion to all sources of revenue.



Following is a schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 2020-2021. The schedule reflects cash received during fiscal year 2020-2021 and revenue committed to the American Heart Association that will be received in future years.

2020-2021 Corporate Funding Received from Pharmaceutical and Biotech Companies and Device Manufacturers		
Corporation	Total Cash Received During 2020-2021 on Prior and Current Year Commitments (1)	2020-2021 Commitments Receivable in the Future
3M	115,000	-
Abbott	322,498	150,000
Alexion Pharmaceuticals Inc.	1,344,000	-
Alnylam Pharmaceuticals	749,340	300,000
AmerisourceBergen	126,950	-
Amgen	1,708,085	118,000
AstraZeneca	6,295,000	-
Atricure	50,000	40,000
Bard/BD	60,000	-
Bayer Healthcare	1,787,723	135,000
BMS/Pfizer	75,000	-
Boehringer Ingelheim Pharmaceuticals	4,835,000	4,750,000
Boston Scientific Corporation	115,000	50,000
Bristol Meyers Squibb	50,000	-
Caladrius Biosciences, Inc.	100,000	-
Chiesi	47,500	25,000
CSL Behring	131,450	-
Cytokinetics	425,000	580,000
Edwards Lifesciences LLC	2,309,000	300,000
Esperion Therapeutics, Inc.	-	135,000
Genentech	961,000	-
GSK Consumer Healthcare	79,000	-
iRhythm	50,000	-
Jabil	65,000	-
Janssen	435,000	93,000
Janssen Biotech	120,000	-
Jazz Pharmaceuticals	250,000	-
Johnson & Johnson	135,125	-
Kaneka Pharma America, LLC	151,750	186,250
Kiniksa Pharmaceuticals (UK)	-	575,000
Lantheus Medical Imaging	-	60,000
Medtronic/Covidien/EV3	903,000	455,000
Merck	150,000	-
MicroVention	58,500	-
MyoKardia	965,000	-
Novartis Asia Pacific Pharmaceutical	619,241	187,361
Novartis Pharmaceuticals	1,661,764	18,106,874
NovoNordisk	1,631,500	11,500
Parker Hannifin	62,500	-
Pfizer	767,750	100,000
Reckitt & Benckiser	50,000	-
Regeneron	75,000	-
Roche Diagnostics	75,000	-
Sage Therapeutics	-	300,000
Sanofi	1,681,710	-
Schiller Americas, Inc.	88,500	-
Siemens Healthineers	77,500	-
Tylenol	664,899	-
Verily (Google Life Science)	5,440,753	-
Totals	37,866,039	26,657,985

NOTE: (1) Includes all cash received from corporate contributions and earned revenue greater than \$50,000. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2015-2016 through fiscal year 2020-2021.